自2020年始，药通中国论坛系列活动已成功举办16届，招募包括医药、医疗器械、基金、生物园区在内的海内外医疗创新企业，聚集海内外医药及投融资界顶尖BD与管理人员，为项目交流搭建高效的沟通渠道，为资产交易创造宝贵机会。
本次药通中国秋季论坛将举行三天（中国时间2024年9月24日至25日（现场直播）和27日（录播VoD）。以下是论坛日程表及9月25日上午创新药授权路演、9月27日创新医药出海专场（点播）公司介绍。
3F Waste Recovery is a company dedicated to transforming fish waste into high-value products like marine collagen and pet supplements. The company specializes in using sustainable, environmentally friendly methods to create innovative products that serve various industries, including health, beauty, and biotechnology. One of its key products is pure marine collagen derived from cod skins, enabling advanced medical, military, robotics, and pharmaceutical applications. The company not only generates value from what would otherwise be waste but also aims to revolutionize the industry by manufacturing and licensing technologies to make cleaner, higher-quality products for global markets. Through partnerships with fish processors and other stakeholders, 3F Waste Recovery helps maximize resource efficiency while contributing to the circular economy, demonstrating that Doing Good, is Good Business.
Members of the research group come from China Pharmaceutical University, Jiangsu Key Laboratory of Drug Design and Optimization, Central nervous system drug research and development team.
At present, the members of the team include Associate Professor Shi Lei from the Department of Medicinal Chemistry, Associate Professor Li Tingting from the Department of Pharmacology, Associate Professor Liu Lisha from the Department of Pharmacy, and Associate Professor Liu Jing from the Department of Pharmaceutical Analysis, as well as more than 20 Master and doctoral students, with self-discipline, diligent analytical thinking, and keen adaptability in learning.
Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) is a leading pharmaceutical company in China, specializing in the research, development, production, and commercialization of drugs for various therapeutic areas such as cardiovascular diseases, tumors, perioperative care, gastrointestinal disorders, and urologic diseases. It was established through a joint venture between CP Group from Thailand and Jiangsu Nongken Group. NJCTTQ is renowned for its commitment to innovation and quality, making it a key player in the global pharmaceutical industry. As the most important subsidiary of Sino Biopharmaceutical Limited, listed on the Hong Kong Stock Exchange under the code 1177, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ) is among the top 30 pharmaceutical companies in China. CTTQ is actively expanding its international business, having received GMP basis approval from both the EU Health Authority and the US FDA. The company boasts a diverse and specialized product pipeline, focusing on areas such as liver diseases, oncology, respiratory diseases, antibiotics, and diabetes.
Evecxia is dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification, building a stronger more resilient endogenous serotonin system. Evecxia is Phase 2-ready with two unique drug candidates addressing large unmet needs in mood disorders:
EVX-101: Oral tablet for next-line therapy in depression and obsessive-compulsive disorder patients responding inadequately to first-line SSRI antidepressants.
EVX-301: IV infusion for patients hospitalized with suicidal ideation crisis.
EVX-101 and EVX-301 are risk-mitigated as efficacy and safety are founded in clinical data.
MediSieve is an innovative BioTech company based in the White City Innovation District of West London. A spin-off from University College London, MediSieve has developed a technology called Magnetic Blood Filtration, a transformative platform that provides the ability physically remove or isolate specific substances directly from the bloodstream of patients. The company has a pipeline of both internal and partnered assets targeting large underserved conditions and patient populations in areas including gene therapy, oncology, autoimmune disesaes and inflammation. Different assets provide value by either removing harmful agents that cause disease or prevent therapies, or by isolating valuable agents for downstream use such as diagnostics.
GV20 Therapeutics is a biopharmaceutical company focused on developing innovative therapies, particularly in the field of immunotherapy. They aim to harness the body’s immune system to combat diseases, including cancer. The company is known for its work on treatments that may enhance the efficacy of existing therapies or provide new options for patients with unmet medical needs. Their approach often involves utilizing cutting-edge technologies and research to create novel drug candidates that can target specific pathways in the immune response.
Regencor is a biotechnology company focused on developing regenerative therapies for cardiovascular diseases. The company aims to harness the body’s natural healing mechanisms to restore heart function and improve patient outcomes, particularly for those with heart failure and related conditions.
Regencor’s research often centers on innovative approaches, such as using stem cell technology or other regenerative strategies, to promote tissue repair and regeneration in the heart. They are dedicated to translating scientific discoveries into effective treatments that can significantly impact patient lives.
Legacy Healthcare is developing transformative medicines for the treatment of autoimmune and inflammatory diseases, with an immune-sparing mode of action, allowing safe chronic use. The first drug, Coacillium cutaneous solution has been filed for approval with EMA for the treatment of alopecia areata, a debilitating autoimmune dermatological disease with an intense psychological impact on all patients, especially in children.
Minomic is a biotechnology company focused on developing innovative diagnostic tools for the early detection and monitoring of cancer. Their primary product, MiCheck™, is a blood test designed to detect prostate cancer with greater accuracy than traditional methods.
Minomic aims to improve patient outcomes by providing more precise diagnostics that can help tailor treatment options and reduce unnecessary procedures. The company leverages advanced biomarker technology and a strong research foundation to enhance cancer detection and management.
Cyclarity Therapeutics is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. Their research aims to address significant unmet medical needs, particularly in conditions like Alzheimer’s disease and other forms of dementia.
Cyclarity is known for its commitment to leveraging advanced scientific approaches and technologies to discover and develop new treatments that can slow disease progression and improve patient quality of life. The company’s pipeline often includes novel compounds that target underlying disease mechanisms.
